Does DURVALUMAB Cause Immune-mediated hypophysitis? 14 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Immune-mediated hypophysitis have been filed in association with DURVALUMAB (IMFINZI). This represents 0.1% of all adverse event reports for DURVALUMAB.
14
Reports of Immune-mediated hypophysitis with DURVALUMAB
0.1%
of all DURVALUMAB reports
3
Deaths
6
Hospitalizations
How Dangerous Is Immune-mediated hypophysitis From DURVALUMAB?
Of the 14 reports, 3 (21.4%) resulted in death, 6 (42.9%) required hospitalization, and 3 (21.4%) were considered life-threatening.
Is Immune-mediated hypophysitis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DURVALUMAB. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does DURVALUMAB Cause?
Death (2,817)
Malignant neoplasm progression (1,330)
Pneumonitis (827)
Radiation pneumonitis (786)
Pyrexia (573)
Diarrhoea (530)
Pneumonia (453)
Dyspnoea (444)
Interstitial lung disease (430)
Off label use (395)
What Other Drugs Cause Immune-mediated hypophysitis?
NIVOLUMAB (171)
PEMBROLIZUMAB (137)
IPILIMUMAB (135)
CARBOPLATIN (59)
PACLITAXEL (42)
CYCLOPHOSPHAMIDE (33)
EPIRUBICIN (23)
BEVACIZUMAB (12)
DOXORUBICIN (11)
LENVATINIB (10)
Which DURVALUMAB Alternatives Have Lower Immune-mediated hypophysitis Risk?
DURVALUMAB vs DUTASTERIDE
DURVALUMAB vs DUTASTERIDE\TAMSULOSIN
DURVALUMAB vs DUVELISIB
DURVALUMAB vs DYDROGESTERONE
DURVALUMAB vs EBASTINE